SCHEMBL23727737

SCHEMBL23727737

O=C(O)N=c1scc(C(F)(F)F)n1Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.39
PLA2G1B P04054 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
RAB9A P51151 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37
LMNA P02545 5/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
TSHR P16473 2/20 0.36
EGLN1 Q9GZT9 1/20 0.36
POLB P06746 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
RGS4 P49798 1/20 0.35
RGS8 P57771 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
XBP1 P17861 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23727735 1.00 L3MBTL1 (0.39) L3MBTL1PLA2G1BATG4BRAB9AHSD17B10
SCHEMBL23749770 0.84 ALDH1A1 (0.45) L3MBTL1RAB9AHSD17B10GSK3BLMNA
SCHEMBL9520206 0.77 GSK3B (0.51) L3MBTL1GSK3AGSK3BLMNASMN1; SMN2
SCHEMBL23727302 0.77 RAB9A (0.42) L3MBTL1RAB9AHSD17B10GSK3AGSK3B
SCHEMBL23727791 0.77 RAB9A (0.45) L3MBTL1RAB9AHSD17B10GSK3AGSK3B
SCHEMBL23727789 0.77 RAB9A (0.45) L3MBTL1RAB9AHSD17B10GSK3AGSK3B
SCHEMBL23727301 0.77 RAB9A (0.42) L3MBTL1RAB9AHSD17B10GSK3AGSK3B
SCHEMBL23727102 0.75 HSD17B10 (0.39) RAB9AHSD17B10GSK3AGSK3BLMNA
SCHEMBL23727101 0.75 HSD17B10 (0.39) RAB9AHSD17B10GSK3AGSK3BLMNA
SCHEMBL23749771 0.74 LMNA (0.47) L3MBTL1RAB9AGSK3AGSK3BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
EP-4100008-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS The Rockefeller University (US) 2022-12-14 EP disclosed
WO-2021158936-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS LATS2, LATS1, YAP1 L3MBTL1 639/4885PLA2G1B 3181/4885ATG4B 4503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.